The MET Receptor Tyrosine Kinase as a Therapeutic Target in Multiple MyelomaChristine M Stellrecht*
Department of Experimental Therapeutics, UT MD Anderson Cancer Center, Houston, Texas 77030, USA
- Corresponding Author:
- Christine M Stellrecht
Department of Experimental Therapeutics
UT MD Anderson Cancer Center
Houston, Texas 77030, USA
E-mail: [email protected]
Received Date: April 25, 2014; Accepted Date: April 30, 2014; Published Date: May 09, 2014
Citation: Stellrecht CM (2014) The MET Receptor Tyrosine Kinase in Multiple Myeloma. J Leuk (Los Angel) 2:e107. doi: 10.4172/2329-6917.1000e107
Copyright: © 2014 Stellrecht CM. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author andsource are credited.
Multiple Myeloma (MM) is a progressive and debilitating B-cell disorder typified by the accumulation and dissemination of malignant plasma cells in the bone marrow which subsequently induce osteolytic lesions.Despite recent advancement of new therapies for MM, patients ultimately develop drug resistanceand succumb to the disease. This highlights the need to increase our understanding of the disease and to identify new myeloma targets for drug development.